Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/02/017873
CTRI/2019/02/017873
Not yet recruiting
Phase 2

A phase II trial to study efficacy, toxicity and immunomodulatory effect of Carctol-S in high grade serous epithelial ovarian cancer at first serological relapse.

Central Council for Research in Ayurvedic Sciences Ministry of AYUSH Government of India0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Central Council for Research in Ayurvedic Sciences Ministry of AYUSH Government of India
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Central Council for Research in Ayurvedic Sciences Ministry of AYUSH Government of India

Eligibility Criteria

Inclusion Criteria

  • •1\.Patients with high grade serous ovarian cancer who attained complete response to front line treatment and experienced first serological relapse.
  • •2\.European Cooperative Oncology Group (ECOG) Performance score is less than or equal to 1\. 3\.No evidence of disease on clinical examination. 4\.No or minimal disease on CE\-CT (abdomen, pelvis and thorax)

Exclusion Criteria

  • •1\.Symptomatic patients.
  • •2\.Patients with evidence of disease on clinical examination.
  • •3\.Patients with evidence of significant disease on radiological
  • •4\.Patients who did not attain CR to frontline primary treatment.
  • •5\.Inability to follow up at regular intervals.
  • •6\.Inability to take oral medication

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
To evaluate the impact of PET scan based radiotherapy planning for cervical cancer in Indian women.Health Condition 1: null- Carcinoma cervix
CTRI/2016/05/006924Department of Biotechnology Government of India60
Active, not recruiting
Phase 1
Trastuzumab and AUY922 in HER2-aberrant NSCLCAdvanced non-smallcell lung cancer with HER2 - overexpression or - amplification or - mutationMedDRA version: 17.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-005655-13-DEniversity of Cologne29
Active, not recruiting
Phase 1
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibitiolocally advanced esophageal adenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10001173Term: Adenocarcinoma of esophagusSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-003048-22-DEniversität zu Köln56
Not yet recruiting
Phase 2
A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or -amplification or - mutation.HER2-overexpression or -amplification or -mutationC34Malignant neoplasm of bronchus and lung
DRKS00003301niversität Köln29
Active, not recruiting
Phase 1
Treatment of advanced adenocarcinoma of the lungAdult patients with either firstly diagnosed or relapsed advanced adenocarcinoma of the lung harbouring ROS1 translocationMedDRA version: 17.1Level: LLTClassification code 10025032Term: Lung adenocarcinoma NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-002737-38-ATniversity of Cologne30